Literature DB >> 29540348

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Michael Hallek1,2, Bruce D Cheson3, Daniel Catovsky4, Federico Caligaris-Cappio5, Guillermo Dighiero6, Hartmut Döhner7, Peter Hillmen8, Michael Keating9, Emili Montserrat10, Nicholas Chiorazzi11, Stephan Stilgenbauer7, Kanti R Rai11, John C Byrd12, Barbara Eichhorst1, Susan O'Brien13, Tadeusz Robak14, John F Seymour15, Thomas J Kipps16.   

Abstract

The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29540348     DOI: 10.1182/blood-2017-09-806398

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  293 in total

1.  Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.

Authors:  Chuan Tong; Yajing Zhang; Yang Liu; Xingyu Ji; Wenying Zhang; Yelei Guo; Xiao Han; Dongdong Ti; Hanren Dai; Chunmeng Wang; Qingming Yang; Wanli Liu; Yao Wang; Zhiqiang Wu; Weidong Han
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 2.  Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.

Authors:  R Andrew Harkins; Sharvil P Patel; Christopher R Flowers
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 3.  Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies.

Authors:  Prioty Islam; Anthony R Mato
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 4.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

5.  Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.

Authors:  Tycho Baumann; Riccardo Moia; Gianluca Gaidano; Julio Delgado; Adalgisa Condoluci; Neus Villamor; Anil Babu Payedimarri; Dolors Costa; Andrea Patriarca; Carlos Jiménez-Vicente; Davide Rossi; Emili Montserrat
Journal:  Leukemia       Date:  2021-02-04       Impact factor: 11.528

6.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

7.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

8.  Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.

Authors:  Christine E Ryan; Matthew P Cheng; Nicolas C Issa; Jennifer R Brown; Matthew S Davids
Journal:  Blood Adv       Date:  2020-04-14

9.  BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.

Authors:  Victor S Lin; Thomas E Lew; Sasanka M Handunnetti; Piers Blombery; Tamia Nguyen; David A Westerman; Bryone J Kuss; Constantine S Tam; Andrew W Roberts; John F Seymour; Mary Ann Anderson
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

Review 10.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.